Common Contracts
3 similar Contingent Value Rights Agreement contracts by Ligand Pharmaceuticals Inc, Metabasis Therapeutics Inc
EX-10.2 3 dex102.htm FORM OF ROCHE CONTINGENT VALUE RIGHTS AGREEMENT Form of Roche CVR Agreement CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • May 5th, 2020 • New York
THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [ • ] (this “Agreement”, is entered into by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Buyer”), Metabasis Therapeutics, Inc., a Delaware corporation (“Target”), David F. Hale, as Stockholders’ Representative (the “Stockholders’ Representative”), and Mellon Investor Services LLC, a New Jersey limited liability company, as Rights Agent (the “Rights Agent”) and as initial Roche CVR Registrar (as defined herein).
CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • January 28th, 2010 • Metabasis Therapeutics Inc • Pharmaceutical preparations • New York
THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of January 27, 2010 (this “Agreement”, is entered into by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Buyer”), Metabasis Therapeutics, Inc., a Delaware corporation (“Target”), David F. Hale, as Stockholders’ Representative (the “Stockholders’ Representative”), and Mellon Investor Services LLC, a New Jersey limited liability company, as Rights Agent (the “Rights Agent”) and as initial Roche CVR Registrar (as defined herein).
Form of Roche CVR Agreement CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • October 28th, 2009 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [ • ] (this “Agreement”, is entered into by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Buyer”), Metabasis Therapeutics, Inc., a Delaware corporation (“Target”), David F. Hale, as Stockholders’ Representative (the “Stockholders’ Representative”), and Mellon Investor Services LLC, a New Jersey limited liability company, as Rights Agent (the “Rights Agent”) and as initial Roche CVR Registrar (as defined herein).
